0P0000ZP87.F — Fidelity Global Healthcare Y-Dis-EUR (ETF)
Price: $29.75
· 1 day: -2.81% · 5 days: -0.60% · 1 month: +0.00% · YTD: -1.06%
As of 2026-10-08 20:00 UTC.
52-week range: $26.79 – $31.27 (currently at 66% of the range).
The read
0P0000ZP87.F is in a turning up, momentum firm. $29.92 is the level overhead; $29.19 the first support below.
3 of 6 technical checks lean bullish.
Price vs 50-day: below
Price vs 200-day: above
50d vs 200d avg: above
MACD: bullish
RSI momentum: 50
5-day tape: -0.6%
Trend
Turning up · below 50-day & 200-day
Momentum
RSI 49.86 · neutral · MACD bullish
Trend strength
ADX 23.8 · developing
Location
-0.6% vs 50-day MA
52-week range
-5% from high · +11% from low
Volatility
ATR 0.25 · ~0.8%/day
Key levels
Level
Type
Distance
$29.92 (resistance)
sma 50
0.57%
$30.43 (resistance)
swing zone
2.29%
$31.27 (resistance)
52w high
5.11%
$29.19 (support)
sma 200
-1.88%
$28.7 (support)
swing zone
-3.53%
$28.14 (support)
swing zone
-5.41%
Indicators
RSI (14)
49.86
MACD
0.0696
ADX (14)
23.8
ATR (14)
0.25
50-day average
$29.92
200-day average
$29.19
Latest 0P0000ZP87.F news
FTSE 100 rises as AstraZeneca lifts healthcare sector — London's FTSE 100 edged higher on Tuesday, gaining 0.34% to 10,721.48 points, driven by strength in the healthcare sector. The advance followed AstraZeneca's agreement to acquire a $2 billion stake in Summit Therapeutics (Reuters, 2026-09-29)
Jim Cramer warns that buying stocks now means 'fighting the Federal Reserve' — CNBC's Jim Cramer warned that buying stocks after the Federal Reserve's quarter-point rate hike to a range of 3.75%-4% means 'fighting the Fed,' a difficult position for investors. The Fed's first hike in three years was (CNBC, 2026-09-16)
Goldman picks China healthcare stocks for a post-AI trade — Goldman Sachs identifies Chinese healthcare stocks as attractive investment opportunities following strong second-quarter earnings growth, as investors seek alternatives to crowded AI-related sectors. Nearly half of MSCI (CNBC, 2026-09-13)
Chinese Biotech Overtakes AI as Emerging-Market Growth Trade — Investors in emerging markets are rotating away from artificial intelligence stocks toward Chinese biotech as a preferred high-growth trade. Bloomberg's EM technology index has fallen into a bear market over the past mon (Bloomberg Business, 2026-07-27)
Council Post: Why Biotech Companies Shouldn't Fear Criticism — Alice Gilman, founder and COO of R3 Bio, argues that biotechnology and pharmaceutical companies should not fear public criticism and can instead leverage attention for commercial gain. Speaking at a Boston industry event (Forbes, 2026-07-24)
Oil Tops $98 a Barrel, Tech Earnings Worry Markets — Oil prices surged above $98 per barrel amid escalating geopolitical tensions in the Middle East, including ongoing U.S. military strikes against Iran and reported attacks by Houthi rebels on Saudi oil tankers in the Red (The Wall Street Journal, 2026-07-23)